242 related articles for article (PubMed ID: 18165630)
1. Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?
Booth CM; Tannock I
J Clin Oncol; 2008 Jan; 26(1):6-8. PubMed ID: 18165630
[No Abstract] [Full Text] [Related]
2. Society of Interventional Radiology Interventional Oncology Task Force: interventional oncology research vision statement and critical assessment of the state of research affairs.
Goldberg SN; Bonn J; Dodd G; Dupuy D; Geschwind JH; Hicks M; Hume KM; Lee FT; Lewis CA; Lencioni RA; Omary RA; Rundback JH; Silverman S; Dorfman GS;
J Vasc Interv Radiol; 2005 Oct; 16(10):1287-94. PubMed ID: 16221897
[No Abstract] [Full Text] [Related]
3. The scientific basis of clinical trials: statistical aspects.
Gehan EA
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2587-90. PubMed ID: 9815661
[TBL] [Abstract][Full Text] [Related]
4. Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results.
Tannock I; Murphy K
J Clin Oncol; 1983 Jan; 1(1):66-70. PubMed ID: 6668484
[No Abstract] [Full Text] [Related]
5. Highlights from the 29th European Society for Medical Oncology Congress: Vienna, Austria, October 29 through November 2, 2004.
Price N
Clin Prostate Cancer; 2004 Dec; 3(3):136-40. PubMed ID: 15636678
[No Abstract] [Full Text] [Related]
6. Improving the institutional submission and approval process for clinical research protocols in oncology.
Camacho LH; Marubio L; Purdom MA; Leonard D; Hong DS; Moulder S; Pilat SR; Kurzrock R
J Clin Oncol; 2007 Apr; 25(12):1632-3. PubMed ID: 17443009
[No Abstract] [Full Text] [Related]
7. [Results of questionnaire to 56 medical institutions about clinical trials of cancer chemotherapy].
Kurihara M; Matsukawa M; Satoh A; Shimada K; Asaumi H
Gan To Kagaku Ryoho; 1999 Jun; 26(7):916-25. PubMed ID: 10396318
[TBL] [Abstract][Full Text] [Related]
8. The phase III candidate: can we improve the science of selection?
Bajorin D
J Clin Oncol; 2004 Jan; 22(2):211-3. PubMed ID: 14665614
[No Abstract] [Full Text] [Related]
9. [Critical reading of a clinical trial in oncopneumology].
Kreisman H; Charloux A
Rev Pneumol Clin; 1994; 50(1):1-2. PubMed ID: 7973325
[No Abstract] [Full Text] [Related]
10. Long overdue: phase II studies in older cancer patients: where does the FDA stand?
Balducci L; Tam-McDevitt J; Hauser R; Simon J
J Clin Oncol; 2008 Mar; 26(8):1387-88. PubMed ID: 18323564
[No Abstract] [Full Text] [Related]
11. Influence of measurement error on response rates.
Warr D; McKinney S; Tannock I
Cancer Treat Rep; 1985 Oct; 69(10):1127-32. PubMed ID: 4042092
[No Abstract] [Full Text] [Related]
12. Computer-aided documentation and therapy planning in pediatric oncology.
Wiedemann T; Knaup P; Bachert A; Creutzig U; Haux R; Schilling F
Stud Health Technol Inform; 1998; 52 Pt 2():1306-9. PubMed ID: 10384671
[TBL] [Abstract][Full Text] [Related]
13. An efficient design for phase III studies of combination chemotherapies.
Ellenberg SS; Eisenberger MA
Cancer Treat Rep; 1985 Oct; 69(10):1147-54. PubMed ID: 4042093
[No Abstract] [Full Text] [Related]
14. Cancer clinical trials: the emergence and development of a new style of practice.
Keating P; Cambrosio A
Bull Hist Med; 2007; 81(1):197-223. PubMed ID: 17369668
[TBL] [Abstract][Full Text] [Related]
15. Geriatric oncology aims for clinical trials.
Sinha G
J Natl Cancer Inst; 2006 Nov; 98(21):1516-8. PubMed ID: 17077352
[No Abstract] [Full Text] [Related]
16. [Active studies of the Working Association for Urological Oncology (AUO) in 2006].
Rexer H
Urologe A; 2006 Feb; 45(2):229-40. PubMed ID: 16440204
[No Abstract] [Full Text] [Related]
17. Health care disparity: an overlooked problem in phase I oncology trials.
O'Brien TE
J Clin Oncol; 2007 Jul; 25(21):3182-3. PubMed ID: 17634502
[No Abstract] [Full Text] [Related]
18. The changing landscape of urologic oncology: initiating systemic therapies, interventional skills, and clinical trials. Introduction.
Lin DW; Shore ND
Urol Oncol; 2012; 30(4 Suppl):S1. PubMed ID: 22795074
[No Abstract] [Full Text] [Related]
19. Cost effectiveness, chemotherapy, and the clinician.
Griggs JJ; Sorbero ME
Breast Cancer Res Treat; 2009 Apr; 114(3):597-8. PubMed ID: 18695985
[No Abstract] [Full Text] [Related]
20. A positive step forward, but more needed to maximize cost benefits of new-generation cancer therapies.
Haines IE
J Clin Oncol; 2007 Sep; 25(25):e31-2. PubMed ID: 17761966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
